View ValuationInogen 향후 성장Future 기준 점검 0/6Inogen은 연간 수입과 매출이 각각 51.4%와 6.3% 증가할 것으로 예상되고 EPS는 연간 36.6%만큼 증가할 것으로 예상됩니다.핵심 정보51.4%이익 성장률36.64%EPS 성장률Medical Equipment 이익 성장13.4%매출 성장률6.3%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트15 May 2026최근 향후 성장 업데이트공고 • Feb 25+ 1 more updateInogen, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026Inogen, Inc. provided earnings guidance for the first quarter and full year 2026. The company expects first quarter 2026 reported revenue to be in line with first quarter 2025, due to channel mix and lower expected U.S. rentals revenue driven by reimbursement mix and reduced patients on service. For the full year 2026, the company expects reported revenue in the range of $366 million to $373 million, reflecting approximately 6% growth at the midpoint of the range relative to the Company’s 2025 revenue.공고 • Nov 05Inogen, Inc. Provides Earnings Guidance for Fourth Quarter and Reiterates Revenue Guidance for the Full Year 2025Inogen, Inc. provided earnings guidance for fourth quarter and reiterated revenue guidance for the full year 2025. For the quarter, the company expects reported revenue in the range of $87 million to $90 million, reflecting approximately 10% year-over-year growth at the midpoint of the range, compared to the Company’s fourth quarter 2024 revenue. For the year, the company is reiterating its reported revenue outlook in the range of $354 million to $357 million, reflecting approximately 6% growth at the midpoint, when compared to the Company’s 2024 revenue.공고 • Aug 08Inogen, Inc. Provides Earnings Guidance for Third Quarter and Full Year 2025Inogen, Inc. provided earnings guidance for third quarter and full year 2025. For the quarter, the company expects reported revenue in the range of $91 million to $93 million, reflecting approximately 4% year-over-year growth at the midpoint of the range, relative to the Company’s third quarter 2024 revenue. For the full year 2025, the company expects reported revenue in the range of $354 million to $357 million, reflecting approximately 6% growth at the midpoint of the range, relative to the Company’s 2024 revenue.공고 • May 08Inogen, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2025Inogen, Inc. provided earnings guidance for the second quarter and full year 2025. For the second quarter of 2025, the company expects reported revenue in the range of $89 million to $91 million, reflecting flat to approximately 3% growth, relative to the Company’s second quarter 2024 revenue. For the full year 2025, the company continues to expect reported revenue in the range of $352 million to $355 million, reflecting 5% to 6% growth relative to the Company’s 2024 revenue.공고 • Feb 26Inogen, Inc. Provides Revenue Guidance for the First Quarter 2025 and Full Year 2025Inogen, Inc. provided revenue guidance for the first quarter 2025 and full year 2025. For the first quarter 2025, the company expects revenue in the range of $79 million to $81 million, reflecting 1% to 4% reported growth relative to the Company’s first quarter 2024 revenue. For the full year 2025, company expects revenue in the range of $352 million to $355 million, reflecting 5% to 6% growth relative to the Company’s 2024 revenue.공고 • Jan 14+ 1 more updateInogen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024 and Full Year 2024Inogen, Inc. provided revenue guidance for the fourth quarter of 2024 and full year 2024. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2024 to be in the range of $79.0 million to $80.0 million, reflecting year-over-year growth of 4% to 5%. The Company estimates preliminary, unaudited total revenue for the full year 2024 to be in the range of $334.5 million to $335.5 million, reflecting year-over-year growth of 6% exceeding Inogen’s previously announced full year 2024 guidance range of $329 million to $331 million. For the year, performance was driven by strong double-digit growth in business-to-business revenue while the company continues to work to stabilize direct-to-consumer revenue with initiatives to enhance overall profitability.모든 업데이트 보기Recent updates공고 • Jul 16Inogen, Inc. to Report Q2, 2026 Results on Aug 06, 2026Inogen, Inc. announced that they will report Q2, 2026 results on Aug 06, 2026공고 • Jul 02Inogen, Inc. Announces Appointment of Andrew (Andy) Reding as Executive Vice President, Chief Operating Officer, Effective July 6, 2026On June 2, 2026, the Board of Directors (Board) of Inogen, Inc. (the Company) appointed Andrew (Andy) Reding to serve as Executive Vice President, Chief Operating Officer (COO) of the Company, effective July 6, 2026. Andy Reding, 56, was responsible for driving revenue and operational performance, aligning cross-functional priorities, and helping ensure Inogen’s strategy was translated into efficient and measurable outcomes. Andy Reding joined Inogen with more than 30 years of leadership experience across medical technology, commercial operations, product development, and healthcare reimbursement. Most recently, he served as Chief Commercial Officer of Viant Medical, where for more than six years he led teams supporting complex medical-device design and manufacturing programs. Across 25 facilities, Viant served hundreds of medical device companies, including the top companies in the world, and experienced exceptional growth during his tenure. Andy Reding had extensive respiratory care experience as he served as Vice President and General Manager of Hillrom Respiratory Health, where he led sales, marketing, customer service, research and development, reimbursement, and third-party billing. During his tenure, his team expanded the sales force, developed new products, and successfully navigated FDA and CMS requirements to bring innovative products to market. Andy Reding held a Master of Business Administration from the University of South Carolina and a bachelor’s degree from Marquette University.공고 • Apr 23Inogen, Inc. to Report Q1, 2026 Results on May 07, 2026Inogen, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026공고 • Apr 21Inogen, Inc., Annual General Meeting, Jun 05, 2026Inogen, Inc., Annual General Meeting, Jun 05, 2026.공고 • Apr 07Inogen, Inc. Appoints Vafa Jamali as Class I Independent Director, Effective on the Date of the Company’s 2026 Annual Meeting, or June 15, 2026Inogen, Inc. announced the appointment of Vafa Jamali as Class I independent director to the Inogen Board of Directors, effective on the date of the Company’s 2026 Annual Meeting, or June 15, 2026 if earlier, with a term expiring at the Company’s 2027 annual meeting of stockholders or until his successor is duly elected and qualified. The Board also appointed Mr. Jamali to the Audit Committee of the Board (the Audit Committee) and the Compliance Committee of the Board (the Compliance Committee), effective as of the Effective Date. Mr. Jamali, 56, served as Chairman and Chief Executive Officer of ZimVie Inc., a medical technology company, from February 2021 to November 2025, where he led the company’s Nasdaq listing following the spin-out from Zimmer Biomet and helped each of the businesses (Spine and Dental) through significant portfolio optimization actions to support a turnaround to higher growth and profitability. Previously, Mr. Jamali served as the Chief Commercial Officer of Rockley Photonics, a silicon photonics company, where he led commercial strategic planning for the early-stage company from October 2020 until joining ZimVie. Prior to that, Mr. Jamali served as Senior Vice President and President, Respiratory, Gastrointestinal and Informatics (“RGI”) of Medtronic plc from May 2017 until October 2020. Before leading the RGI business, he served as Senior Vice President and President, Early Technologies of Medtronic plc from January 2016 until May 2017 and prior to that he served as Vice President and General Manager, GI Solutions of Medtronic plc from January 2015 until January 2016. Before joining Medtronic, Mr. Jamali held leadership positions with Covidien plc, Cardinal Health, Inc. and Baxter International Inc. Mr. Jamali currently serves on the board of directors of Baylis Medical Technologies, a private medical device company, and Eptam Plastics, a private medical equipment manufacturer. Mr. Jamali received his Bachelor of Commerce degree with distinction from the University of Alberta in Edmonton, Canada.공고 • Mar 31+ 1 more updateInogen, Inc. Announces Chief Financial Officer Changes, Effective April 6, 2026Inogen, Inc. has appointed Jason Richardson as Chief Financial Officer, effective April 6, 2026. Mr. Richardson succeeds Michael Bourque, who will step down from his role as Chief Financial Officer on that date. Mr. Bourque will serve in an advisory capacity until June 30, 2026, to ensure a smooth transition. Mr. Richardson joins Inogen from Baxter International Inc., where he most recently served as Chief Financial Officer and Vice President of the Healthcare Systems & Technologies segment, a $3 billion publicly reported business. In this role, he was a central figure in Baxter’s integration of Hillrom, driving growth initiatives and improved operating performance. Prior to Baxter’s acquisition of Hillrom, Mr. Richardson held a variety of senior finance leadership roles at Hillrom, including overseeing its Respiratory Care franchise, a durable medical equipment (DME) business focused on cystic fibrosis, bronchiectasis, and other respiratory diseases.공고 • Feb 25+ 1 more updateInogen, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026Inogen, Inc. provided earnings guidance for the first quarter and full year 2026. The company expects first quarter 2026 reported revenue to be in line with first quarter 2025, due to channel mix and lower expected U.S. rentals revenue driven by reimbursement mix and reduced patients on service. For the full year 2026, the company expects reported revenue in the range of $366 million to $373 million, reflecting approximately 6% growth at the midpoint of the range relative to the Company’s 2025 revenue.공고 • Jan 12Inogen, Inc. to Report Q4, 2025 Results on Feb 24, 2026Inogen, Inc. announced that they will report Q4, 2025 results on Feb 24, 2026공고 • Jan 07Inogen, Inc. Announces the Launch of Aurora CPAP Masks for Obstructive Sleep Apnea in the United StatesInogen, Inc. announced the launch of Aurora CPAP masks, a new product within the expanding Inogen portfolio. Aurora's introduction marks a significant milestone in Inogen's strategy to expand its respiratory care portfolio and now bring quality, high-performing masks to patients indicated for obstructive sleep apnea (OSA). Engineered for superior comfort, reliability, and usability, Aurora Masks establishes Inogen's presence in the growing sleep-therapy market and expands Inogen's addressable market opportunity. The company intends to leverage its existing distribution channels and partnerships to bring Aurora CPAP masks to customers and strengthen relationships with providers. Aurora Masks launch is supported by a patient-use study, in which the majority of patients reported being highly satisfied with the Aurora masks1. The Aurora Mask portfolio--which includes the F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows--is specifically designed to meet the diverse needs of most patients using CPAP devices. Aurora Masks provide options for different facial structures and therapy needs, promoting patient-focused care and encouraging consistent use in sleep and respiratory therapy. Key Features: High-Quality Headgear: features a triple-material design with ultrasonic edge sealing technology, promoting comfort and durability. Com comfortable Cushion Design: Medical-grade rebound silicone cushion is soft, airtight, and hypoallergenic - designed to reduce facial pressure and improve patient fit and comfort. Quiet Honeycomb Vent Design: Promotes a peaceful sleep environment for users and partners. Simple Maintenance: Easy to assemble, disassemble, and clean for everyday convenience. Universal Compatibility: Works seamlessly with most CPAP devices. FDA 510(k) Cleared: Meets rigorous safety and performance standards. Aurora CPAP masks are now offered through certified partners.공고 • Nov 05Inogen, Inc. Provides Earnings Guidance for Fourth Quarter and Reiterates Revenue Guidance for the Full Year 2025Inogen, Inc. provided earnings guidance for fourth quarter and reiterated revenue guidance for the full year 2025. For the quarter, the company expects reported revenue in the range of $87 million to $90 million, reflecting approximately 10% year-over-year growth at the midpoint of the range, compared to the Company’s fourth quarter 2024 revenue. For the year, the company is reiterating its reported revenue outlook in the range of $354 million to $357 million, reflecting approximately 6% growth at the midpoint, when compared to the Company’s 2024 revenue.공고 • Oct 15Inogen, Inc. to Report Q3, 2025 Results on Nov 05, 2025Inogen, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 05, 2025공고 • Sep 26Inogen, Inc. Appoints Naga Rameswamy as Chief Technology Officer, Effective September 29, 2025Inogen, Inc. announced the appointment of Naga Rameswamy as Chief Technology Officer, effective September 29, 2025. Mr. Rameswamy joins Inogen from Alcon, where he served as the Vice President and Global Head of Digital Health Platforms. Mr. Rameswamy brings more than two decades of leadership in the medical device industry spanning innovation, R&D, and digital transformation. Prior to Alcon, he spent nearly twenty years at GE Healthcare, culminating as Vice President of Digital Health Engineering. He has advanced secure device connectivity, remote diagnostics, fleet reliability, and care management platforms across diagnostic imaging, ultrasound, and patient monitoring modalities. He has scaled global engineering teams and partnered closely with quality, regulatory, manufacturing, sales, service, and cloud infrastructure to deliver compliant, secure, and intuitive products & solutions that improve serviceability, extend product lifecycles, and enhance experiences for patients, caregivers, and clinicians.공고 • Aug 08Inogen, Inc. Provides Earnings Guidance for Third Quarter and Full Year 2025Inogen, Inc. provided earnings guidance for third quarter and full year 2025. For the quarter, the company expects reported revenue in the range of $91 million to $93 million, reflecting approximately 4% year-over-year growth at the midpoint of the range, relative to the Company’s third quarter 2024 revenue. For the full year 2025, the company expects reported revenue in the range of $354 million to $357 million, reflecting approximately 6% growth at the midpoint of the range, relative to the Company’s 2024 revenue.공고 • Jul 17Inogen, Inc. to Report Q2, 2025 Results on Aug 07, 2025Inogen, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025공고 • Jun 24Inogen, Inc. Introduces Voxi 5 Stationary Oxygen Concentrator: Setting a New Standard in Affordable, Durable Oxygen TherapyInogen, Inc. announced the launch of VoxiTM 5, a new stationary oxygen concentrator (SOC) designed to enhance access to high-quality oxygen therapy for long-term care patients in the United States. As the latest addition to Inogen's product portfolio, Voxi 5 augments the company's line of portable oxygen concentrators, significantly expanding the market potential while leveraging existing sales channels. The Voxi 5 stationary oxygen concentrator combines affordability with durability, setting a new standard in oxygen therapy. Developed in collaboration with Yuwell Medical, Voxi 5 presents a viable option for patients seeking reliable stationary oxygen therapy, delivering 1-5 L/min of quiet1, pure2, continuous flow oxygen in a compact3 and efficient design. The device also features caster wheels to allow for worry free movement between rooms in the home, providing enhanced mobility and ease-of-use. Voxi 5 complements the Inogen At Home®? product by offering a value-driven solution for price-sensitive customers or those in need of an additional unit for multi-room use. The Voxi 5 further solidifies Inogen's position as a pioneer in the home oxygen therapy market, offering patients and healthcare providers a reliable and efficient solution for managing chronic respiratory conditions. Key Features: Quiet Operation: Promoting a peaceful home environment. Compact Design: Includes lockable casters for ease of movement. 3-Year Sieve Bed Warranty: Providing reliable, long-term performance. Advanced Filtration: Features an 8-layer internal gas pathway for delivering medical-grade oxygen. The Voxi 5 is available for purchase through Inogen's website and authorized partners.공고 • May 08Inogen, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2025Inogen, Inc. provided earnings guidance for the second quarter and full year 2025. For the second quarter of 2025, the company expects reported revenue in the range of $89 million to $91 million, reflecting flat to approximately 3% growth, relative to the Company’s second quarter 2024 revenue. For the full year 2025, the company continues to expect reported revenue in the range of $352 million to $355 million, reflecting 5% to 6% growth relative to the Company’s 2024 revenue.공고 • Apr 16Inogen, Inc. to Report Q1, 2025 Results on May 07, 2025Inogen, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025공고 • Mar 28Inogen, Inc., Annual General Meeting, May 14, 2025Inogen, Inc., Annual General Meeting, May 14, 2025.공고 • Feb 26Inogen, Inc. Provides Revenue Guidance for the First Quarter 2025 and Full Year 2025Inogen, Inc. provided revenue guidance for the first quarter 2025 and full year 2025. For the first quarter 2025, the company expects revenue in the range of $79 million to $81 million, reflecting 1% to 4% reported growth relative to the Company’s first quarter 2024 revenue. For the full year 2025, company expects revenue in the range of $352 million to $355 million, reflecting 5% to 6% growth relative to the Company’s 2024 revenue.공고 • Feb 04Inogen, Inc. Announces Board ChangesInogen, Inc. announced the appointment of Mira Kirti Sahney to Inogen’s Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. Mira Sahney serves as a board member of Claria Medical, a privately held minimally invasive surgical tools company. She joined Claria Medical’s board in 2017. Previously, Ms. Sahney served as the President of the Pelvic Health Operating Unit at Medtronic from 2021 to 2024. Before joining Medtronic, Ms. Sahney served as President, Chief Executive Officer, and Director of Hyalex Orthopaedics, a venture-backed medical device innovator from 2017 to 2021. Prior to Hyalex, she served in leadership roles at Smith + Nephew, including as Senior Vice President and General Manager of both the Ear, Nose and Throat and the Gynecology businesses. She began her medical technology career as co-founder and President of Myomo, Inc., a wearable medical robotics company addressing neurological disorders. Ms. Sahney graduated summa cum laude from the University of Michigan with a B.S. in Mechanical Engineering. She holds an M.S. from Stanford University in Mechanical Engineering. Ms. Sahney also holds both an M.S. in Engineering and an MBA from the Massachusetts Institute of Technology. In connection with the appointment, Ms. Sahney will be joining the Compliance Committee as well as the Nominating and Governance Committee of the Board.공고 • Jan 27Inogen, Inc. announced that it expects to receive $27.209763 million in funding from Yuwell (Hong Kong) Holdings LimitedInogen, Inc. announced that it has entered into a securities purchase agreement to issue 2,626,425 shares at a price of $10.36 per share for the gross proceeds pf $10.36 for the total gross proceeds of $27,209,763 on January 25, 2025. The transaction will include participation from Yuwell (Hong Kong) Holdings Limited. The closing of the Private Placement is expected to occur during the first quarter of 2025.공고 • Jan 14+ 1 more updateInogen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024 and Full Year 2024Inogen, Inc. provided revenue guidance for the fourth quarter of 2024 and full year 2024. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2024 to be in the range of $79.0 million to $80.0 million, reflecting year-over-year growth of 4% to 5%. The Company estimates preliminary, unaudited total revenue for the full year 2024 to be in the range of $334.5 million to $335.5 million, reflecting year-over-year growth of 6% exceeding Inogen’s previously announced full year 2024 guidance range of $329 million to $331 million. For the year, performance was driven by strong double-digit growth in business-to-business revenue while the company continues to work to stabilize direct-to-consumer revenue with initiatives to enhance overall profitability.공고 • Dec 31Inogen, Inc. Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance DeviceInogen, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SIMEOX 200 Airway Clearance Device, expanding the company's ability to market and meet the various needs of patients with chronic respiratory diseases in the U.S. SIMEOX 200 is the next-generation of the original Simeox (currently available in select international markets). It is intended to promote and improve bronchial drainage by enhancing mobilization of bronchial secretions via high frequency oscillatory vibrations and intermittent negative pressure to the airway during exhalation. The device is intended to be prescribed for use in patients capable of independently generating cough. SIMEOX 200 is predominantly aimed to help patients with chronic lung diseases associated with mucus hypersecretion and mucus retention, such as Bronchiectasis, COPD (Chronic Obstructive Pulmonary Diseases), Cystic Fibrosis or Primary Ciliary Dyskinesia. Traditional airway clearance therapies can be time consuming and constraining with mixed results. SIMEOX 200 provides an innovative alternative, delivering efficient bronchial drainage, specifically in low lung volumes, that can be administered in healthcare centers and institutions, as well as at home. Inogen plans to pursue a limited launch of SIMEOX 200 in targeted sites in 2025.New Risk • Nov 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$34m net loss in 2 years). Shareholders have been diluted in the past year (2.2% increase in shares outstanding).Reported Earnings • Nov 09Third quarter 2024 earnings released: US$0.25 loss per share (vs US$1.97 loss in 3Q 2023)Third quarter 2024 results: US$0.25 loss per share (improved from US$1.97 loss in 3Q 2023). Revenue: US$88.8m (up 5.8% from 3Q 2023). Net loss: US$5.96m (loss narrowed 87% from 3Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.공고 • Nov 08Inogen, Inc. Provides Revenue Guidance for the Full Year 2024Inogen, Inc. provided revenue guidance for the full year 2024. The company expects revenue for the full year 2024 to range from approximately $329 million to $331 million, which represents approximately 4% to 5% growth over the Company’s prior year revenue.공고 • Oct 17Inogen, Inc. to Report Q3, 2024 Results on Nov 07, 2024Inogen, Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024공고 • Oct 09Inogen Launches Rove 4 Portable Oxygen Concentrator, Delivering the Highest Oxygen Output in the Lightest Weight 4-Setting PocInogen, Inc. announced that it has commenced the U.S. market release of the Inogen® Rove 4™ Portable Oxygen Concentrator. With an additional, fourth flow setting delivering up to 840ml/min of medical grade oxygen, in a lightweight user-friendly design of less than 3 lbs and three battery configurations providing up to 5 hours and 45 minutes of operation, the versatility of Rove 4 empowers patients with choices that may help them with normal activities of daily living. The Rove 4 utilizes Inogen’s patented pulse-dose Intelligent Delivery Technology. This technology provides unparalleled triggering sensitivity to quickly detect a breath and deliver oxygen within the first 250 milliseconds of the inspiration, where oxygen has the most effect on lung gas exchange. Designed for reliability, the Rove 4 offers a best-in-class expected service life of up to 8 years.New Risk • Aug 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$40m net loss in 2 years). Shareholders have been diluted in the past year (2.3% increase in shares outstanding). Significant insider selling over the past 3 months (€79k sold).New Risk • Aug 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.7% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$45m net loss in 2 years). Significant insider selling over the past 3 months (€79k sold).Reported Earnings • Aug 07Second quarter 2024 earnings released: US$0.24 loss per share (vs US$0.42 loss in 2Q 2023)Second quarter 2024 results: US$0.24 loss per share (improved from US$0.42 loss in 2Q 2023). Revenue: US$88.8m (up 6.1% from 2Q 2023). Net loss: US$5.59m (loss narrowed 43% from 2Q 2023). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 20 percentage points per year, which is a significant difference in performance.공고 • Aug 07Inogen, Inc. Provides Revenue Guidance for the Full Year 2024Inogen, Inc. provided revenue guidance for the full year 2024. The company expects revenue for the full year 2024 to range from approximately $325 million to $330 million, which represents approximately 3% to 5% growth over the Company’s prior year revenue.공고 • Jul 16Inogen, Inc. to Report Q2, 2024 Results on Aug 06, 2024Inogen, Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024공고 • Jul 04Inogen, Inc. Appoints Kevin P. Smith as General Counsel and Executive Vice President, Business Development, Effective July 22, 2024Inogen, Inc. announced the appointment of Kevin P. Smith as General Counsel and Executive Vice President, Business Development, effective July 22, 2024. Mr. Smith joins Inogen from Sirtex Medical, where he served as General Counsel and Executive Vice President, Business Development, since 2018. Mr. Smith brings nearly thirty years of experience to the Company. Prior to joining Sirtex, Kevin served as vice president and associate general counsel at Flexion Therapeutics, focusing on securities requirements, business development, and intellectual property. Previously, he was general counsel for the Danaher Life Sciences Platform. He has also held senior legal leadership positions within Novartis Pharmaceuticals. Before moving in-house, Mr. Smith worked for multinational law firms in New York, Silicon Valley, and London.공고 • Jun 05Inogen, Inc. Announces Publication of Study Demonstrating the Association of Portable Oxygen Therapy with Decreased Survival and Increased Cost-Effectiveness RatioInogen, Inc. shared the results of a study published in the journal Pulmonary Therapy, demonstrating the association of portable oxygen concentrators with increased survival and cost-effectiveness ratio when compared to other long-term oxygen therapies. The study sourced data from the French national healthcare system database, the Systeme National des Donnees de Sante (SNDS). With a sample size of over 244,000 adult long-term oxygen therapy patients from 2013-2020, it is likely the largest retrospective claims database assessment study of long-term oxygen therapy to date. The results showed that portable oxygen concentrator (POC) use, either alone or in combination with other oxygen modalities, was associated with improved survival and similar healthcare resource use, such as hospitalizations and specialist visits, compared to stationary concentrators, compressed tanks and liquid oxygen. Additionally, based on the incremental cost-effectiveness ratio (ICER), POCs were cost-effective compared to stationary concentrators, compression tanks, and liquid oxygen. In a secondary analysis of the POC group, two sub-groups were classified based on device autonomy i.e. higher mobility and lower mobility groups. Within the POC group, the higher mobility POC sub-group were associated with better survival, lower healthcare resource use and lower related costs vs the lower mobility POC sub-group.Recent Insider Transactions • May 15Executive VP recently sold €79k worth of stockOn the 10th of May, Jason Somer sold around 10k shares on-market at roughly €7.95 per share. This transaction amounted to 69% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • May 08First quarter 2024 earnings released: US$0.62 loss per share (vs US$0.88 loss in 1Q 2023)First quarter 2024 results: US$0.62 loss per share (improved from US$0.88 loss in 1Q 2023). Revenue: US$78.0m (up 8.1% from 1Q 2023). Net loss: US$14.6m (loss narrowed 28% from 1Q 2023). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 31 percentage points per year, which is a significant difference in performance.공고 • May 08Inogen, Inc. Provides Revenue Guidance for the Second Quarter of 2024Inogen, Inc. provided revenue guidance for the second quarter of 2024. For the second quarter of 2024, the company expects revenue to be in the range of $81 million to $84 million.New Risk • Apr 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$45m net loss in 3 years). Shareholders have been diluted in the past year (2.5% increase in shares outstanding).공고 • Apr 20Inogen, Inc., Annual General Meeting, Jun 05, 2024Inogen, Inc., Annual General Meeting, Jun 05, 2024, at 10:00 Pacific Standard Time. Agenda: To elect two Class I directors from the nominees described in this proxy statement; to ratify the appointment of Deloitte & Touche LLP as company independent registered public accounting firm for fiscal year ending December 31, 2024; to approve, on an advisory and non-binding basis, executive compensation as described in this proxy statement; to approve the Inogen, Inc. Amended and Restated 2023 Equity Incentive Plan; and to transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.공고 • Apr 11Inogen, Inc. to Report Q1, 2024 Results on May 07, 2024Inogen, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024공고 • Feb 29Inogen, Inc. Provides Earnings Guidance for the First Quarter 2024Inogen, Inc. provided earnings guidance for the first quarter 2024. For the period, the company expects revenue of $73 to $74 million, reflecting 1% to 3% reported growth relative to the first quarter 2023.Reported Earnings • Feb 28Full year 2023 earnings released: US$4.42 loss per share (vs US$3.67 loss in FY 2022)Full year 2023 results: US$4.42 loss per share (further deteriorated from US$3.67 loss in FY 2022). Revenue: US$315.7m (down 16% from FY 2022). Net loss: US$102.4m (loss widened 22% from FY 2022). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.공고 • Jan 31Inogen, Inc. to Report Q4, 2023 Results on Feb 27, 2024Inogen, Inc. announced that they will report Q4, 2023 results After-Market on Feb 27, 2024공고 • Jan 25+ 1 more updateInogen, Inc. Announces CFO Changes, Effective March 4, 2024On January 21, 2024, the Board of Directors of Inogen, Inc. appointed Michael Bourque to serve as Executive Vice President, Chief Financial Officer and Treasurer of the Company, effective March 4, 2024. Most recently, Mr. Bourque, 60, served as Chief Financial Officer and Treasurer of Chase Corporation since February 2021. He also served as Chief Financial Officer of Keystone Dental, Senior Vice President, Chief Financial Officer and Treasurer of Analogic Corporation from 2014 to 2018 and as Vice President of Finance for Axcelis Technologies from 2011 to 2014. Bourque received a bachelor’s degree in accounting from Bentley University. As a result of the engagement of Mr. Bourque, effective March 4, 2024, Michael Sergesketter, the Company’s interim Executive Vice President, Chief Financial Officer and Treasurer, will no longer be considered an executive officer of the Company or hold the position of Executive Vice President, Chief Financial Officer and Treasurer, but will remain employed with the Company pursuant to his employment contract to assist with the transition of his duties.공고 • Jan 05Inogen, Inc. Appoints Grgoire Ramade to Serve as Chief Commercial OfficerOn January 2, 2024, the Board of Directors (Board) of Inogen, Inc. appointed Grgoire Ramade to serve as Chief Commercial Officer (CCO) of the Company, effective January 2, 2024. Most recently, Mr. Ramade, 54, served as the company's Senior Vice President of International Sales from November 2023. Prior to joining the company, Mr. Ramade served as Senior Vice President and Chief Commercial Officer of Vapotherm, Inc. from October 2020 to October 2023 and as Vice President, International Sales and Worldwide Marketing of Vapotherm, Inc. since May 2016. Mr. Ramade worked at Becton Dickinson Medical-Pharmaceutical Systems as Vice President of Global Marketing and Business Development from January 2013 to May 2016. He also held the positions of Senior Marketing Director Home Healthcare Solution at Philips Healthcare from 2010 to 2012, Marketing Director EMEA at Philips Respironics from 2005 to 2009 and Product Manager of Consumable Masks and Accessories at Philips Respironics from 2004 to 2005. Mr. Ramade holds a bachelors degree in International Business with a minor in Economics from the American University of Paris and an MBA in International Business and Marketing from the Ecole Nationale des Ponts et Chausses School of International Management.공고 • Nov 29Inogen, Inc. Announces Separation Agreement with Nabil ShabshabInogen, Inc. announced Nabil Shabshab Separation Agreement; Resignation as a Director. The company announced dated November 10, 2023, Mr. Shabshab’s role as an officer and employee of the Company ended effective November 10, 2023.공고 • Nov 14+ 1 more updateInogen Announces CEO ChangesInogen, Inc. announced that its Board of Directors has appointed Kevin Smith as Inogen’s Chief Executive Officer, effective immediately, succeeding Nabil Shabshab. Mr. Smith brings more than 20 years of commercial leadership experience in the medical device industry, including respiratory care and durable medical equipment businesses, and a history of success in executing value-creating transformations across organizations. He most recently served as Chief Executive Officer at Sirtex Medical Limited, a global manufacturer of interventional treatment solutions, where he successfully implemented a profitable growth strategy, including global expansion, and oversaw the company’s business development strategy. Mr. Smith previously held senior positions at Sensium Healthcare Ltd., Teleflex, Hillrom Holdings and ZOLL Medical Corporation. Throughout his career, he has developed extensive expertise strategically navigating enterprises through market cycles, leading business turnarounds, optimizing business channels, introducing new products, and driving growth and international market expansion. Mr. Smith joins Inogen from Sirtex Medical Limited, a previously ASX-listed leading manufacturer of interventional treatment solutions, where he most recently served as Chief Executive Officer since 2019. He originally joined Sirtex in 2017 as Executive Vice President, Sales & Marketing for the Americas, and was responsible for transforming the company’s business development approach, implementing impactful commercial strategies for sustained profitable growth, and leading Sirtex’s expansion into Latin America. From October 2015 to November 2016, Mr. Smith served as Chief Commercial Officer at Sensium Healthcare Ltd., where he was responsible for revising the growth strategy, and eventually arranging a sale of the business to The Surgical Company. Earlier in his career, Mr. Smith held a variety of leadership roles in the global therapeutic and medical device industry, including a seven-year tenure at Teleflex within the cardiac business unit, where he served as Global Vice President of Sales and Marketing, and eventually International Vice President of Sales and Marketing. Key highlights of Mr. Smith’s tenure at Teleflex include leading new product launches, driving sales channel optimization initiatives and implementing strategies to improve gross margins and profitability. Mr. Smithearned an MBA in global management from the University of Phoenix and holds a Bachelor’s degree in marketing from the University of Kentucky.Reported Earnings • Nov 10Third quarter 2023 earnings released: US$1.97 loss per share (vs US$0.41 loss in 3Q 2022)Third quarter 2023 results: US$1.97 loss per share (further deteriorated from US$0.41 loss in 3Q 2022). Revenue: US$84.0m (down 20% from 3Q 2022). Net loss: US$45.7m (loss widened 381% from 3Q 2022). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.New Risk • Oct 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.4m (US$97.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Market cap is less than US$100m (€92.4m market cap, or US$97.6m).공고 • Oct 11Inogen, Inc. to Report Q3, 2023 Results on Nov 07, 2023Inogen, Inc. announced that they will report Q3, 2023 results After-Market on Nov 07, 2023공고 • Sep 08+ 2 more updatesInogen, Inc. Announces Executive ChangesInogen, Inc. announced that On September 1, 2023, Kristin Caltrider, Executive Vice President, Finance, Chief Financial Officer and Treasurer, notified Inogen, Inc. (the Company) of her intention to step down as an officer of the Company effective upon the date a new Executive Vice President, Chief Financial Officer and Treasurer commences employment, which will occur on September 11, 2023. Ms. Caltriders decision was not related to any disagreements with the Company or its management on any matters relating to the Companys operations, policies, or practices. Ms. Caltrider has agreed to remain in a non-executive employee role to assist with the transition of her duties through September 29, 2023. Effective as of September 11, 2023, the Companys board of directors (the Board) appointed Michael K. Sergesketter to serve as the Companys interim Executive Vice President, Chief Financial Officer and Treasurer. Mr. Michael K. Sergesketter, previously served as the Companys interim Executive Vice President, Chief Financial Officer and Treasurer from December 2021 until May 2022. Mr.Sergesketter served as the Vice President and Chief Financial Officer at Kimball Electronics, Inc., an electronics manufacturing company, from October 2014 to July 2021. Prior to the spin-off of Kimball Electronics, Mr. Sergesketter served as the Vice President and Chief Financial Officer for Kimball Electronics Group, Inc., an electronics manufacturing company, from July 1996 to October 2014. Prior to Kimball Electronics Group, Mr. Sergesketter served as Vice President of Audit and Management Services at Kimball International, Inc. from January 1991 to June 1996. Prior to that, Mr. Sergesketter held various internal audit roles at Kimball International, Inc. from June 1981 to January 1991. Mr. Sergesketter holds a B.S. in accounting from University of Southern Indiana.Reported Earnings • Aug 08Second quarter 2023 earnings released: US$0.42 loss per share (vs US$0.15 loss in 2Q 2022)Second quarter 2023 results: US$0.42 loss per share (further deteriorated from US$0.15 loss in 2Q 2022). Revenue: US$83.6m (down 19% from 2Q 2022). Net loss: US$9.83m (loss widened 186% from 2Q 2022). Revenue is forecast to grow 1.1% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.공고 • Aug 08Inogen, Inc. Announces the Introduction of the Rove 6(Tm) Portable Oxygen Concentrators in the United StatesInogen, Inc. announced the introduction of the Rove 6(TM) portable oxygen concentrator in the United States with best in class 8-year expected service life. The Inogen(R) Rove 6(TM) was launched in Europe in December 2022. Having completed the necessary regulatory processes, the expected service life of the Rove 6 will be extended from 5 years to 8 years for all Rove 6 devices sold worldwide. The 8 year best-in-class expected service life has also been extended to Inogen One(R) G5 portable oxygen concentrators in the US. The Inogen®? Rove 6(TM) is a 6-setting portable oxygen concentrator that also provides the longest battery life of any portable oxygen concentrator currently available on the market. This device delivers up to 1,260 mL/minute of medical grade oxygen at a weight of only 4.8 pounds. The Inogen(R") Rove 6(TM) is available with two battery options, including an extended battery that can support a battery life up to 12 hours and 45 minutes.공고 • Aug 02Inogen, Inc. Announces Board ChangesInogen, Inc. and George Parr, Executive Vice President and Chief Commercial Officer of the Company, mutually determined that Mr. Parr would separate from the Company on or before July 31, 2023. On an interim basis, Nabil Shabshab, President and Chief Executive Officer, will manage the commercial and marketing teams to drive the Company forward and ensure business continuity during this transition period.공고 • Jul 14+ 1 more updateInogen, Inc. to Report Q2, 2023 Results on Aug 07, 2023Inogen, Inc. announced that they will report Q2, 2023 results After-Market on Aug 07, 2023공고 • May 07Inogen, Inc. Reiterates Earnings Guidance for the Year 2023Inogen, Inc. reiterated earnings guidance for the year 2023. The company expects total company revenue for the full year 2023 to grow in the low to mid digits. The company remains focused on its return to profitability by the fourth quarter of 2023.Reported Earnings • May 06First quarter 2023 earnings released: US$0.88 loss per share (vs US$0.63 loss in 1Q 2022)First quarter 2023 results: US$0.88 loss per share (further deteriorated from US$0.63 loss in 1Q 2022). Revenue: US$72.2m (down 10% from 1Q 2022). Net loss: US$20.3m (loss widened 43% from 1Q 2022). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 26Full year 2022 earnings released: US$3.67 loss per share (vs US$0.28 loss in FY 2021)Full year 2022 results: US$3.67 loss per share (further deteriorated from US$0.28 loss in FY 2021). Revenue: US$377.2m (up 5.4% from FY 2021). Net loss: US$83.8m (loss widened US$77.4m from FY 2021). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.공고 • Feb 11Inogen, Inc. Announces Bart Sanford to Step Down as Executive Vice President, Operations Effective on or Before March 1, 2023On February 6, 2023, Inogen, Inc. (the “Company”) and Bart Sanford, Executive Vice President, Operations of the Company, mutually determined that Mr. Sanford would separate from the Company on or before March 1, 2023. In connection with Mr. Sanford’s separation as Executive Vice President, Operations, Mr. Sanford and the Company entered into a transition agreement and release, whereby Mr. Sanford agreed to provide transition services to the Company in his current role until, at the latest, March 1, 2023.공고 • Jan 11+ 1 more updateInogen, Inc. to Report Q4, 2022 Results on Feb 23, 2023Inogen, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Feb 23, 2023Board Change • Nov 16High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Heather Rider is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Nov 03Third quarter 2022 earnings released: US$0.41 loss per share (vs US$0.54 profit in 3Q 2021)Third quarter 2022 results: US$0.41 loss per share (down from US$0.54 profit in 3Q 2021). Revenue: US$105.4m (up 13% from 3Q 2021). Net loss: US$9.51m (down 178% from profit in 3Q 2021). Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance.공고 • Nov 03Inogen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022Inogen, Inc. provided revenue guidance for the fourth quarter of 2022. The company now projects revenue for the fourth quarter of 2022 to be in the range of approximately $87 million to $92 million, or approximately 14% to 20% growth year-over-year.공고 • Oct 06Inogen, Inc. to Report Q3, 2022 Results on Nov 02, 2022Inogen, Inc. announced that they will report Q3, 2022 results Pre-Market on Nov 02, 2022Reported Earnings • Aug 06Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.23 profit in 2Q 2021)Second quarter 2022 results: US$0.15 loss per share (down from US$0.23 profit in 2Q 2021). Revenue: US$103.4m (up 1.8% from 2Q 2021). Net loss: US$3.44m (down 168% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.Board Change • Aug 06High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Heather Rider is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공고 • Jul 09Inogen, Inc. to Report Q2, 2022 Results on Aug 04, 2022Inogen, Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 04, 2022공고 • Jun 26+ 1 more updateInogen, Inc.(NasdaqGS:INGN) dropped from Russell 2000 Growth-Defensive IndexInogen, Inc.(NasdaqGS:INGN) dropped from Russell 2000 Growth-Defensive Index공고 • May 19Inogen, Inc. Names Agnes Lee as Senior Vice President of Investor Relations and Strategic Planning, Effective May 23, 2022Inogen, Inc. announced the appointment of Agnes Lee to the position of Senior Vice President of Investor Relations and Strategic Planning, effective May 23, 2022. Agnes joins Inogen from Butterfly Network, where she served as Vice President of Investor Relations. Prior to Butterfly, she led proactive investor relations programs at Fluidigm and ResMed, Inc.공고 • May 06+ 1 more updateInogen, Inc. Provides Earnings Guidance for the Second Quarter of 2022Inogen, Inc. provided earnings guidance for the second quarter of 2022. For the period, the company expects total revenue for the second quarter of 2022 to improve sequentially and to be in line with the same period in 2021.Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Independent Director Heather Rider is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공고 • Apr 22Inogen, Inc., Annual General Meeting, Jun 08, 2022Inogen, Inc., Annual General Meeting, Jun 08, 2022, at 10:00 Pacific Standard Time. Agenda: To elect three Class II directors from the nominees described in the proxy statement; to ratify the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2022; to approve, on an advisory and non-binding basis, executive compensation as described in this proxy statement; and to transact other business that may properly come before the Annual Meeting, or any adjournments or postponements thereof.공고 • Apr 20Inogen, Inc. Announces Management ChangesInogen, Inc. announced that this Amendment No. 1 to Current Report on Form 8-K/A (the “Amendment”) amends the Current Report on Form 8-K of Inogen, Inc. (the “Company”) dated March 22, 2022 and filed with the Commission on March 23, 2022 (the “Original Form 8-K”), which disclosed the appointment of each of Kevin King, Mary Kay Ladone, and Glenn Boehnlein to the Board of Directors of the Company (the “Board”), effective March 22, 2022. At the time of filing of the Original Form 8-K, as disclosed in the Original Form 8-K, the Board appointed Mr. King as a member of the Audit Committee of the Board (the “Audit Committee”) and chairperson of the Compensation Committee of the Board (the “Compensation Committee”), Ms. Ladone as a member of the Audit Committee and the Compensation Committee, and Mr. Boehnlein as chairperson of the Audit Committee. At the time of filing the Original Form 8-K, no determination had been made with respect to the appointment of any such directors to the Compliance Committee of the Board (the “Compliance Committee”). This Amendment is being filed solely to report that on April 14, 2022, upon the recommendation of the Nominating and Governance Committee of the Board, the Board appointed Mr. Boehnlein to the Compliance Committee, effective immediately. Effective upon such appointment, the members of the Compliance Committee are Elizabeth Mora (Chair), Kristen Miranda, and Glenn Boehnlein.공고 • Apr 15Inogen, Inc. to Report Q1, 2022 Results on May 05, 2022Inogen, Inc. announced that they will report Q1, 2022 results After-Market on May 05, 2022Board Change • Apr 02High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Independent Director Heather Rider is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공고 • Mar 06+ 1 more updateInogen, Inc. Executive ChangesOn March 1, 2022, the Board of Directors of Inogen, Inc. appointed Kristin A. Caltrider to serve as the Company's Executive Vice President and Treasurer, effective March 21, 2022. Ms. Caltrider will succeed Michael Sergesketter, interim Executive Vice President, and Treasurer, who, on March 2, 2022, tendered his resignation as an officer of the Company effective upon the date Ms. Caltrider commences employment. Mr. Sergesketter will provide transition services pursuant to the terms of his existing offer letter with the Company through no later than June 24, 2022. Most recently, Ms. Caltrider, 54, served as the Vice President of Finance at Quidel Corporation, a manufacturer of medical diagnostic products, since June 2014.Reported Earnings • Feb 26Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: US$0.28 loss per share (down from US$0.27 loss in FY 2020). Revenue: US$358.0m (up 16% from FY 2020). Net loss: US$6.33m (loss widened 8.6% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 4.0%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.공고 • Jan 30Loren McFarland Not to Stand for Re-Election as Director of Inogen, IncOn January 6, 2022, Loren McFarland informed Inogen, Inc. that he will not stand for re-election at the Company’s 2022 annual meeting of stockholders.공고 • Jan 12Inogen, Inc. Provides Preliminary Unaudited Revenue Guidance for the Three-Month and Twelve-Month Periods Ended December 31, 2021Inogen, Inc. provided preliminary unaudited revenue guidance for the three-month and twelve-month periods ended December 31, 2021. For the three months, the company expects revenue to be in the range of $75.9 to $76.9 million, up 2.6% to 3.9% from the same period in 2020.For the year, the company expects revenue to be in the range of $357.5 to $358.5 million, up 15.9% to 16.2% from 2020.Reported Earnings • Nov 07Third quarter 2021 earnings released: EPS US$0.54 (vs US$0.077 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$93.1m (up 25% from 3Q 2020). Net income: US$12.2m (up US$13.9m from 3Q 2020). Profit margin: 13% (up from net loss in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 05Second quarter 2021 earnings released: EPS US$0.23 (vs US$0.12 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$101.6m (up 42% from 2Q 2020). Net income: US$5.10m (up 98% from 2Q 2020). Profit margin: 5.0% (up from 3.6% in 2Q 2020).공고 • Jun 28+ 4 more updatesInogen, Inc.(NasdaqGS:INGN) dropped from Russell 3000E Value IndexInogen, Inc.(NasdaqGS:INGN) dropped from Russell 3000E Value Index이익 및 매출 성장 예측DB:6IO - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028417-10019212/31/2027397-13118312/31/2026369-22-5933/31/2026351-25-10-1N/A12/31/2025349-23-22-11N/A9/30/2025347-25-24-13N/A6/30/2025343-26-22-8N/A3/31/2025340-27-21-6N/A12/31/2024336-36-116N/A9/30/2024332-53-146N/A6/30/2024327-92-201N/A3/31/2024322-97-26-2N/A12/31/2023316-102-30-3N/A9/30/2023328-133-43-16N/A6/30/2023349-96-55-27N/A3/31/2023369-90-50-26N/A12/31/2022377-84-59-38N/A9/30/2022366-50-36-16N/A6/30/2022353-28-31-9N/A3/31/2022351-20-203N/A12/31/2021358-6024N/A9/30/202135611933N/A6/30/2021337-22043N/A3/31/2021307-51939N/A12/31/2020308-61937N/A9/30/2020313-21630N/A6/30/202033162938N/A3/31/2020360143643N/A12/31/201936221N/A41N/A9/30/201937032N/A44N/A6/30/201937342N/A43N/A3/31/201936946N/A46N/A12/31/201835852N/A60N/A9/30/201833541N/A61N/A6/30/201830932N/A64N/A3/31/201827626N/A60N/A12/31/201724921N/A60N/A9/30/201723727N/A53N/A6/30/201722225N/A44N/A3/31/201721224N/A39N/A12/31/201620321N/A31N/A9/30/201619219N/A38N/A6/30/201617917N/A41N/A3/31/201616813N/A37N/A12/31/201515912N/A38N/A9/30/20151489N/A30N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 6IO 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: 6IO 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: 6IO 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: 6IO 의 수익(연간 6.3%)이 German 시장(연간 6.6%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: 6IO 의 수익(연간 6.3%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 6IO의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/19 21:54종가2026/07/17 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Inogen, Inc.는 9명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Anderson SchockB. Riley Securities, Inc.Ilya ZubkovFreedom BrokerMatthew MishanKeyBanc Capital Markets Inc.6명의 분석가 더 보기
공고 • Feb 25+ 1 more updateInogen, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026Inogen, Inc. provided earnings guidance for the first quarter and full year 2026. The company expects first quarter 2026 reported revenue to be in line with first quarter 2025, due to channel mix and lower expected U.S. rentals revenue driven by reimbursement mix and reduced patients on service. For the full year 2026, the company expects reported revenue in the range of $366 million to $373 million, reflecting approximately 6% growth at the midpoint of the range relative to the Company’s 2025 revenue.
공고 • Nov 05Inogen, Inc. Provides Earnings Guidance for Fourth Quarter and Reiterates Revenue Guidance for the Full Year 2025Inogen, Inc. provided earnings guidance for fourth quarter and reiterated revenue guidance for the full year 2025. For the quarter, the company expects reported revenue in the range of $87 million to $90 million, reflecting approximately 10% year-over-year growth at the midpoint of the range, compared to the Company’s fourth quarter 2024 revenue. For the year, the company is reiterating its reported revenue outlook in the range of $354 million to $357 million, reflecting approximately 6% growth at the midpoint, when compared to the Company’s 2024 revenue.
공고 • Aug 08Inogen, Inc. Provides Earnings Guidance for Third Quarter and Full Year 2025Inogen, Inc. provided earnings guidance for third quarter and full year 2025. For the quarter, the company expects reported revenue in the range of $91 million to $93 million, reflecting approximately 4% year-over-year growth at the midpoint of the range, relative to the Company’s third quarter 2024 revenue. For the full year 2025, the company expects reported revenue in the range of $354 million to $357 million, reflecting approximately 6% growth at the midpoint of the range, relative to the Company’s 2024 revenue.
공고 • May 08Inogen, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2025Inogen, Inc. provided earnings guidance for the second quarter and full year 2025. For the second quarter of 2025, the company expects reported revenue in the range of $89 million to $91 million, reflecting flat to approximately 3% growth, relative to the Company’s second quarter 2024 revenue. For the full year 2025, the company continues to expect reported revenue in the range of $352 million to $355 million, reflecting 5% to 6% growth relative to the Company’s 2024 revenue.
공고 • Feb 26Inogen, Inc. Provides Revenue Guidance for the First Quarter 2025 and Full Year 2025Inogen, Inc. provided revenue guidance for the first quarter 2025 and full year 2025. For the first quarter 2025, the company expects revenue in the range of $79 million to $81 million, reflecting 1% to 4% reported growth relative to the Company’s first quarter 2024 revenue. For the full year 2025, company expects revenue in the range of $352 million to $355 million, reflecting 5% to 6% growth relative to the Company’s 2024 revenue.
공고 • Jan 14+ 1 more updateInogen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024 and Full Year 2024Inogen, Inc. provided revenue guidance for the fourth quarter of 2024 and full year 2024. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2024 to be in the range of $79.0 million to $80.0 million, reflecting year-over-year growth of 4% to 5%. The Company estimates preliminary, unaudited total revenue for the full year 2024 to be in the range of $334.5 million to $335.5 million, reflecting year-over-year growth of 6% exceeding Inogen’s previously announced full year 2024 guidance range of $329 million to $331 million. For the year, performance was driven by strong double-digit growth in business-to-business revenue while the company continues to work to stabilize direct-to-consumer revenue with initiatives to enhance overall profitability.
공고 • Jul 16Inogen, Inc. to Report Q2, 2026 Results on Aug 06, 2026Inogen, Inc. announced that they will report Q2, 2026 results on Aug 06, 2026
공고 • Jul 02Inogen, Inc. Announces Appointment of Andrew (Andy) Reding as Executive Vice President, Chief Operating Officer, Effective July 6, 2026On June 2, 2026, the Board of Directors (Board) of Inogen, Inc. (the Company) appointed Andrew (Andy) Reding to serve as Executive Vice President, Chief Operating Officer (COO) of the Company, effective July 6, 2026. Andy Reding, 56, was responsible for driving revenue and operational performance, aligning cross-functional priorities, and helping ensure Inogen’s strategy was translated into efficient and measurable outcomes. Andy Reding joined Inogen with more than 30 years of leadership experience across medical technology, commercial operations, product development, and healthcare reimbursement. Most recently, he served as Chief Commercial Officer of Viant Medical, where for more than six years he led teams supporting complex medical-device design and manufacturing programs. Across 25 facilities, Viant served hundreds of medical device companies, including the top companies in the world, and experienced exceptional growth during his tenure. Andy Reding had extensive respiratory care experience as he served as Vice President and General Manager of Hillrom Respiratory Health, where he led sales, marketing, customer service, research and development, reimbursement, and third-party billing. During his tenure, his team expanded the sales force, developed new products, and successfully navigated FDA and CMS requirements to bring innovative products to market. Andy Reding held a Master of Business Administration from the University of South Carolina and a bachelor’s degree from Marquette University.
공고 • Apr 23Inogen, Inc. to Report Q1, 2026 Results on May 07, 2026Inogen, Inc. announced that they will report Q1, 2026 results After-Market on May 07, 2026
공고 • Apr 21Inogen, Inc., Annual General Meeting, Jun 05, 2026Inogen, Inc., Annual General Meeting, Jun 05, 2026.
공고 • Apr 07Inogen, Inc. Appoints Vafa Jamali as Class I Independent Director, Effective on the Date of the Company’s 2026 Annual Meeting, or June 15, 2026Inogen, Inc. announced the appointment of Vafa Jamali as Class I independent director to the Inogen Board of Directors, effective on the date of the Company’s 2026 Annual Meeting, or June 15, 2026 if earlier, with a term expiring at the Company’s 2027 annual meeting of stockholders or until his successor is duly elected and qualified. The Board also appointed Mr. Jamali to the Audit Committee of the Board (the Audit Committee) and the Compliance Committee of the Board (the Compliance Committee), effective as of the Effective Date. Mr. Jamali, 56, served as Chairman and Chief Executive Officer of ZimVie Inc., a medical technology company, from February 2021 to November 2025, where he led the company’s Nasdaq listing following the spin-out from Zimmer Biomet and helped each of the businesses (Spine and Dental) through significant portfolio optimization actions to support a turnaround to higher growth and profitability. Previously, Mr. Jamali served as the Chief Commercial Officer of Rockley Photonics, a silicon photonics company, where he led commercial strategic planning for the early-stage company from October 2020 until joining ZimVie. Prior to that, Mr. Jamali served as Senior Vice President and President, Respiratory, Gastrointestinal and Informatics (“RGI”) of Medtronic plc from May 2017 until October 2020. Before leading the RGI business, he served as Senior Vice President and President, Early Technologies of Medtronic plc from January 2016 until May 2017 and prior to that he served as Vice President and General Manager, GI Solutions of Medtronic plc from January 2015 until January 2016. Before joining Medtronic, Mr. Jamali held leadership positions with Covidien plc, Cardinal Health, Inc. and Baxter International Inc. Mr. Jamali currently serves on the board of directors of Baylis Medical Technologies, a private medical device company, and Eptam Plastics, a private medical equipment manufacturer. Mr. Jamali received his Bachelor of Commerce degree with distinction from the University of Alberta in Edmonton, Canada.
공고 • Mar 31+ 1 more updateInogen, Inc. Announces Chief Financial Officer Changes, Effective April 6, 2026Inogen, Inc. has appointed Jason Richardson as Chief Financial Officer, effective April 6, 2026. Mr. Richardson succeeds Michael Bourque, who will step down from his role as Chief Financial Officer on that date. Mr. Bourque will serve in an advisory capacity until June 30, 2026, to ensure a smooth transition. Mr. Richardson joins Inogen from Baxter International Inc., where he most recently served as Chief Financial Officer and Vice President of the Healthcare Systems & Technologies segment, a $3 billion publicly reported business. In this role, he was a central figure in Baxter’s integration of Hillrom, driving growth initiatives and improved operating performance. Prior to Baxter’s acquisition of Hillrom, Mr. Richardson held a variety of senior finance leadership roles at Hillrom, including overseeing its Respiratory Care franchise, a durable medical equipment (DME) business focused on cystic fibrosis, bronchiectasis, and other respiratory diseases.
공고 • Feb 25+ 1 more updateInogen, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026Inogen, Inc. provided earnings guidance for the first quarter and full year 2026. The company expects first quarter 2026 reported revenue to be in line with first quarter 2025, due to channel mix and lower expected U.S. rentals revenue driven by reimbursement mix and reduced patients on service. For the full year 2026, the company expects reported revenue in the range of $366 million to $373 million, reflecting approximately 6% growth at the midpoint of the range relative to the Company’s 2025 revenue.
공고 • Jan 12Inogen, Inc. to Report Q4, 2025 Results on Feb 24, 2026Inogen, Inc. announced that they will report Q4, 2025 results on Feb 24, 2026
공고 • Jan 07Inogen, Inc. Announces the Launch of Aurora CPAP Masks for Obstructive Sleep Apnea in the United StatesInogen, Inc. announced the launch of Aurora CPAP masks, a new product within the expanding Inogen portfolio. Aurora's introduction marks a significant milestone in Inogen's strategy to expand its respiratory care portfolio and now bring quality, high-performing masks to patients indicated for obstructive sleep apnea (OSA). Engineered for superior comfort, reliability, and usability, Aurora Masks establishes Inogen's presence in the growing sleep-therapy market and expands Inogen's addressable market opportunity. The company intends to leverage its existing distribution channels and partnerships to bring Aurora CPAP masks to customers and strengthen relationships with providers. Aurora Masks launch is supported by a patient-use study, in which the majority of patients reported being highly satisfied with the Aurora masks1. The Aurora Mask portfolio--which includes the F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows--is specifically designed to meet the diverse needs of most patients using CPAP devices. Aurora Masks provide options for different facial structures and therapy needs, promoting patient-focused care and encouraging consistent use in sleep and respiratory therapy. Key Features: High-Quality Headgear: features a triple-material design with ultrasonic edge sealing technology, promoting comfort and durability. Com comfortable Cushion Design: Medical-grade rebound silicone cushion is soft, airtight, and hypoallergenic - designed to reduce facial pressure and improve patient fit and comfort. Quiet Honeycomb Vent Design: Promotes a peaceful sleep environment for users and partners. Simple Maintenance: Easy to assemble, disassemble, and clean for everyday convenience. Universal Compatibility: Works seamlessly with most CPAP devices. FDA 510(k) Cleared: Meets rigorous safety and performance standards. Aurora CPAP masks are now offered through certified partners.
공고 • Nov 05Inogen, Inc. Provides Earnings Guidance for Fourth Quarter and Reiterates Revenue Guidance for the Full Year 2025Inogen, Inc. provided earnings guidance for fourth quarter and reiterated revenue guidance for the full year 2025. For the quarter, the company expects reported revenue in the range of $87 million to $90 million, reflecting approximately 10% year-over-year growth at the midpoint of the range, compared to the Company’s fourth quarter 2024 revenue. For the year, the company is reiterating its reported revenue outlook in the range of $354 million to $357 million, reflecting approximately 6% growth at the midpoint, when compared to the Company’s 2024 revenue.
공고 • Oct 15Inogen, Inc. to Report Q3, 2025 Results on Nov 05, 2025Inogen, Inc. announced that they will report Q3, 2025 results Pre-Market on Nov 05, 2025
공고 • Sep 26Inogen, Inc. Appoints Naga Rameswamy as Chief Technology Officer, Effective September 29, 2025Inogen, Inc. announced the appointment of Naga Rameswamy as Chief Technology Officer, effective September 29, 2025. Mr. Rameswamy joins Inogen from Alcon, where he served as the Vice President and Global Head of Digital Health Platforms. Mr. Rameswamy brings more than two decades of leadership in the medical device industry spanning innovation, R&D, and digital transformation. Prior to Alcon, he spent nearly twenty years at GE Healthcare, culminating as Vice President of Digital Health Engineering. He has advanced secure device connectivity, remote diagnostics, fleet reliability, and care management platforms across diagnostic imaging, ultrasound, and patient monitoring modalities. He has scaled global engineering teams and partnered closely with quality, regulatory, manufacturing, sales, service, and cloud infrastructure to deliver compliant, secure, and intuitive products & solutions that improve serviceability, extend product lifecycles, and enhance experiences for patients, caregivers, and clinicians.
공고 • Aug 08Inogen, Inc. Provides Earnings Guidance for Third Quarter and Full Year 2025Inogen, Inc. provided earnings guidance for third quarter and full year 2025. For the quarter, the company expects reported revenue in the range of $91 million to $93 million, reflecting approximately 4% year-over-year growth at the midpoint of the range, relative to the Company’s third quarter 2024 revenue. For the full year 2025, the company expects reported revenue in the range of $354 million to $357 million, reflecting approximately 6% growth at the midpoint of the range, relative to the Company’s 2024 revenue.
공고 • Jul 17Inogen, Inc. to Report Q2, 2025 Results on Aug 07, 2025Inogen, Inc. announced that they will report Q2, 2025 results After-Market on Aug 07, 2025
공고 • Jun 24Inogen, Inc. Introduces Voxi 5 Stationary Oxygen Concentrator: Setting a New Standard in Affordable, Durable Oxygen TherapyInogen, Inc. announced the launch of VoxiTM 5, a new stationary oxygen concentrator (SOC) designed to enhance access to high-quality oxygen therapy for long-term care patients in the United States. As the latest addition to Inogen's product portfolio, Voxi 5 augments the company's line of portable oxygen concentrators, significantly expanding the market potential while leveraging existing sales channels. The Voxi 5 stationary oxygen concentrator combines affordability with durability, setting a new standard in oxygen therapy. Developed in collaboration with Yuwell Medical, Voxi 5 presents a viable option for patients seeking reliable stationary oxygen therapy, delivering 1-5 L/min of quiet1, pure2, continuous flow oxygen in a compact3 and efficient design. The device also features caster wheels to allow for worry free movement between rooms in the home, providing enhanced mobility and ease-of-use. Voxi 5 complements the Inogen At Home®? product by offering a value-driven solution for price-sensitive customers or those in need of an additional unit for multi-room use. The Voxi 5 further solidifies Inogen's position as a pioneer in the home oxygen therapy market, offering patients and healthcare providers a reliable and efficient solution for managing chronic respiratory conditions. Key Features: Quiet Operation: Promoting a peaceful home environment. Compact Design: Includes lockable casters for ease of movement. 3-Year Sieve Bed Warranty: Providing reliable, long-term performance. Advanced Filtration: Features an 8-layer internal gas pathway for delivering medical-grade oxygen. The Voxi 5 is available for purchase through Inogen's website and authorized partners.
공고 • May 08Inogen, Inc. Provides Earnings Guidance for the Second Quarter and Full Year 2025Inogen, Inc. provided earnings guidance for the second quarter and full year 2025. For the second quarter of 2025, the company expects reported revenue in the range of $89 million to $91 million, reflecting flat to approximately 3% growth, relative to the Company’s second quarter 2024 revenue. For the full year 2025, the company continues to expect reported revenue in the range of $352 million to $355 million, reflecting 5% to 6% growth relative to the Company’s 2024 revenue.
공고 • Apr 16Inogen, Inc. to Report Q1, 2025 Results on May 07, 2025Inogen, Inc. announced that they will report Q1, 2025 results After-Market on May 07, 2025
공고 • Mar 28Inogen, Inc., Annual General Meeting, May 14, 2025Inogen, Inc., Annual General Meeting, May 14, 2025.
공고 • Feb 26Inogen, Inc. Provides Revenue Guidance for the First Quarter 2025 and Full Year 2025Inogen, Inc. provided revenue guidance for the first quarter 2025 and full year 2025. For the first quarter 2025, the company expects revenue in the range of $79 million to $81 million, reflecting 1% to 4% reported growth relative to the Company’s first quarter 2024 revenue. For the full year 2025, company expects revenue in the range of $352 million to $355 million, reflecting 5% to 6% growth relative to the Company’s 2024 revenue.
공고 • Feb 04Inogen, Inc. Announces Board ChangesInogen, Inc. announced the appointment of Mira Kirti Sahney to Inogen’s Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. Mira Sahney serves as a board member of Claria Medical, a privately held minimally invasive surgical tools company. She joined Claria Medical’s board in 2017. Previously, Ms. Sahney served as the President of the Pelvic Health Operating Unit at Medtronic from 2021 to 2024. Before joining Medtronic, Ms. Sahney served as President, Chief Executive Officer, and Director of Hyalex Orthopaedics, a venture-backed medical device innovator from 2017 to 2021. Prior to Hyalex, she served in leadership roles at Smith + Nephew, including as Senior Vice President and General Manager of both the Ear, Nose and Throat and the Gynecology businesses. She began her medical technology career as co-founder and President of Myomo, Inc., a wearable medical robotics company addressing neurological disorders. Ms. Sahney graduated summa cum laude from the University of Michigan with a B.S. in Mechanical Engineering. She holds an M.S. from Stanford University in Mechanical Engineering. Ms. Sahney also holds both an M.S. in Engineering and an MBA from the Massachusetts Institute of Technology. In connection with the appointment, Ms. Sahney will be joining the Compliance Committee as well as the Nominating and Governance Committee of the Board.
공고 • Jan 27Inogen, Inc. announced that it expects to receive $27.209763 million in funding from Yuwell (Hong Kong) Holdings LimitedInogen, Inc. announced that it has entered into a securities purchase agreement to issue 2,626,425 shares at a price of $10.36 per share for the gross proceeds pf $10.36 for the total gross proceeds of $27,209,763 on January 25, 2025. The transaction will include participation from Yuwell (Hong Kong) Holdings Limited. The closing of the Private Placement is expected to occur during the first quarter of 2025.
공고 • Jan 14+ 1 more updateInogen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2024 and Full Year 2024Inogen, Inc. provided revenue guidance for the fourth quarter of 2024 and full year 2024. The Company estimates preliminary, unaudited total revenue in the fourth quarter of 2024 to be in the range of $79.0 million to $80.0 million, reflecting year-over-year growth of 4% to 5%. The Company estimates preliminary, unaudited total revenue for the full year 2024 to be in the range of $334.5 million to $335.5 million, reflecting year-over-year growth of 6% exceeding Inogen’s previously announced full year 2024 guidance range of $329 million to $331 million. For the year, performance was driven by strong double-digit growth in business-to-business revenue while the company continues to work to stabilize direct-to-consumer revenue with initiatives to enhance overall profitability.
공고 • Dec 31Inogen, Inc. Receives FDA 510(k) Clearance for SIMEOX 200 Airway Clearance DeviceInogen, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the SIMEOX 200 Airway Clearance Device, expanding the company's ability to market and meet the various needs of patients with chronic respiratory diseases in the U.S. SIMEOX 200 is the next-generation of the original Simeox (currently available in select international markets). It is intended to promote and improve bronchial drainage by enhancing mobilization of bronchial secretions via high frequency oscillatory vibrations and intermittent negative pressure to the airway during exhalation. The device is intended to be prescribed for use in patients capable of independently generating cough. SIMEOX 200 is predominantly aimed to help patients with chronic lung diseases associated with mucus hypersecretion and mucus retention, such as Bronchiectasis, COPD (Chronic Obstructive Pulmonary Diseases), Cystic Fibrosis or Primary Ciliary Dyskinesia. Traditional airway clearance therapies can be time consuming and constraining with mixed results. SIMEOX 200 provides an innovative alternative, delivering efficient bronchial drainage, specifically in low lung volumes, that can be administered in healthcare centers and institutions, as well as at home. Inogen plans to pursue a limited launch of SIMEOX 200 in targeted sites in 2025.
New Risk • Nov 12New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$34m net loss in 2 years). Shareholders have been diluted in the past year (2.2% increase in shares outstanding).
Reported Earnings • Nov 09Third quarter 2024 earnings released: US$0.25 loss per share (vs US$1.97 loss in 3Q 2023)Third quarter 2024 results: US$0.25 loss per share (improved from US$1.97 loss in 3Q 2023). Revenue: US$88.8m (up 5.8% from 3Q 2023). Net loss: US$5.96m (loss narrowed 87% from 3Q 2023). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.
공고 • Nov 08Inogen, Inc. Provides Revenue Guidance for the Full Year 2024Inogen, Inc. provided revenue guidance for the full year 2024. The company expects revenue for the full year 2024 to range from approximately $329 million to $331 million, which represents approximately 4% to 5% growth over the Company’s prior year revenue.
공고 • Oct 17Inogen, Inc. to Report Q3, 2024 Results on Nov 07, 2024Inogen, Inc. announced that they will report Q3, 2024 results After-Market on Nov 07, 2024
공고 • Oct 09Inogen Launches Rove 4 Portable Oxygen Concentrator, Delivering the Highest Oxygen Output in the Lightest Weight 4-Setting PocInogen, Inc. announced that it has commenced the U.S. market release of the Inogen® Rove 4™ Portable Oxygen Concentrator. With an additional, fourth flow setting delivering up to 840ml/min of medical grade oxygen, in a lightweight user-friendly design of less than 3 lbs and three battery configurations providing up to 5 hours and 45 minutes of operation, the versatility of Rove 4 empowers patients with choices that may help them with normal activities of daily living. The Rove 4 utilizes Inogen’s patented pulse-dose Intelligent Delivery Technology. This technology provides unparalleled triggering sensitivity to quickly detect a breath and deliver oxygen within the first 250 milliseconds of the inspiration, where oxygen has the most effect on lung gas exchange. Designed for reliability, the Rove 4 offers a best-in-class expected service life of up to 8 years.
New Risk • Aug 09New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$40m net loss in 2 years). Shareholders have been diluted in the past year (2.3% increase in shares outstanding). Significant insider selling over the past 3 months (€79k sold).
New Risk • Aug 07New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 8.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (8.7% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (US$45m net loss in 2 years). Significant insider selling over the past 3 months (€79k sold).
Reported Earnings • Aug 07Second quarter 2024 earnings released: US$0.24 loss per share (vs US$0.42 loss in 2Q 2023)Second quarter 2024 results: US$0.24 loss per share (improved from US$0.42 loss in 2Q 2023). Revenue: US$88.8m (up 6.1% from 2Q 2023). Net loss: US$5.59m (loss narrowed 43% from 2Q 2023). Revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 20 percentage points per year, which is a significant difference in performance.
공고 • Aug 07Inogen, Inc. Provides Revenue Guidance for the Full Year 2024Inogen, Inc. provided revenue guidance for the full year 2024. The company expects revenue for the full year 2024 to range from approximately $325 million to $330 million, which represents approximately 3% to 5% growth over the Company’s prior year revenue.
공고 • Jul 16Inogen, Inc. to Report Q2, 2024 Results on Aug 06, 2024Inogen, Inc. announced that they will report Q2, 2024 results After-Market on Aug 06, 2024
공고 • Jul 04Inogen, Inc. Appoints Kevin P. Smith as General Counsel and Executive Vice President, Business Development, Effective July 22, 2024Inogen, Inc. announced the appointment of Kevin P. Smith as General Counsel and Executive Vice President, Business Development, effective July 22, 2024. Mr. Smith joins Inogen from Sirtex Medical, where he served as General Counsel and Executive Vice President, Business Development, since 2018. Mr. Smith brings nearly thirty years of experience to the Company. Prior to joining Sirtex, Kevin served as vice president and associate general counsel at Flexion Therapeutics, focusing on securities requirements, business development, and intellectual property. Previously, he was general counsel for the Danaher Life Sciences Platform. He has also held senior legal leadership positions within Novartis Pharmaceuticals. Before moving in-house, Mr. Smith worked for multinational law firms in New York, Silicon Valley, and London.
공고 • Jun 05Inogen, Inc. Announces Publication of Study Demonstrating the Association of Portable Oxygen Therapy with Decreased Survival and Increased Cost-Effectiveness RatioInogen, Inc. shared the results of a study published in the journal Pulmonary Therapy, demonstrating the association of portable oxygen concentrators with increased survival and cost-effectiveness ratio when compared to other long-term oxygen therapies. The study sourced data from the French national healthcare system database, the Systeme National des Donnees de Sante (SNDS). With a sample size of over 244,000 adult long-term oxygen therapy patients from 2013-2020, it is likely the largest retrospective claims database assessment study of long-term oxygen therapy to date. The results showed that portable oxygen concentrator (POC) use, either alone or in combination with other oxygen modalities, was associated with improved survival and similar healthcare resource use, such as hospitalizations and specialist visits, compared to stationary concentrators, compressed tanks and liquid oxygen. Additionally, based on the incremental cost-effectiveness ratio (ICER), POCs were cost-effective compared to stationary concentrators, compression tanks, and liquid oxygen. In a secondary analysis of the POC group, two sub-groups were classified based on device autonomy i.e. higher mobility and lower mobility groups. Within the POC group, the higher mobility POC sub-group were associated with better survival, lower healthcare resource use and lower related costs vs the lower mobility POC sub-group.
Recent Insider Transactions • May 15Executive VP recently sold €79k worth of stockOn the 10th of May, Jason Somer sold around 10k shares on-market at roughly €7.95 per share. This transaction amounted to 69% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • May 08First quarter 2024 earnings released: US$0.62 loss per share (vs US$0.88 loss in 1Q 2023)First quarter 2024 results: US$0.62 loss per share (improved from US$0.88 loss in 1Q 2023). Revenue: US$78.0m (up 8.1% from 1Q 2023). Net loss: US$14.6m (loss narrowed 28% from 1Q 2023). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 31 percentage points per year, which is a significant difference in performance.
공고 • May 08Inogen, Inc. Provides Revenue Guidance for the Second Quarter of 2024Inogen, Inc. provided revenue guidance for the second quarter of 2024. For the second quarter of 2024, the company expects revenue to be in the range of $81 million to $84 million.
New Risk • Apr 21New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.5% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (14% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$45m net loss in 3 years). Shareholders have been diluted in the past year (2.5% increase in shares outstanding).
공고 • Apr 20Inogen, Inc., Annual General Meeting, Jun 05, 2024Inogen, Inc., Annual General Meeting, Jun 05, 2024, at 10:00 Pacific Standard Time. Agenda: To elect two Class I directors from the nominees described in this proxy statement; to ratify the appointment of Deloitte & Touche LLP as company independent registered public accounting firm for fiscal year ending December 31, 2024; to approve, on an advisory and non-binding basis, executive compensation as described in this proxy statement; to approve the Inogen, Inc. Amended and Restated 2023 Equity Incentive Plan; and to transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
공고 • Apr 11Inogen, Inc. to Report Q1, 2024 Results on May 07, 2024Inogen, Inc. announced that they will report Q1, 2024 results After-Market on May 07, 2024
공고 • Feb 29Inogen, Inc. Provides Earnings Guidance for the First Quarter 2024Inogen, Inc. provided earnings guidance for the first quarter 2024. For the period, the company expects revenue of $73 to $74 million, reflecting 1% to 3% reported growth relative to the first quarter 2023.
Reported Earnings • Feb 28Full year 2023 earnings released: US$4.42 loss per share (vs US$3.67 loss in FY 2022)Full year 2023 results: US$4.42 loss per share (further deteriorated from US$3.67 loss in FY 2022). Revenue: US$315.7m (down 16% from FY 2022). Net loss: US$102.4m (loss widened 22% from FY 2022). Revenue is forecast to grow 4.3% p.a. on average during the next 3 years, compared to a 6.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 52 percentage points per year, which is a significant difference in performance.
공고 • Jan 31Inogen, Inc. to Report Q4, 2023 Results on Feb 27, 2024Inogen, Inc. announced that they will report Q4, 2023 results After-Market on Feb 27, 2024
공고 • Jan 25+ 1 more updateInogen, Inc. Announces CFO Changes, Effective March 4, 2024On January 21, 2024, the Board of Directors of Inogen, Inc. appointed Michael Bourque to serve as Executive Vice President, Chief Financial Officer and Treasurer of the Company, effective March 4, 2024. Most recently, Mr. Bourque, 60, served as Chief Financial Officer and Treasurer of Chase Corporation since February 2021. He also served as Chief Financial Officer of Keystone Dental, Senior Vice President, Chief Financial Officer and Treasurer of Analogic Corporation from 2014 to 2018 and as Vice President of Finance for Axcelis Technologies from 2011 to 2014. Bourque received a bachelor’s degree in accounting from Bentley University. As a result of the engagement of Mr. Bourque, effective March 4, 2024, Michael Sergesketter, the Company’s interim Executive Vice President, Chief Financial Officer and Treasurer, will no longer be considered an executive officer of the Company or hold the position of Executive Vice President, Chief Financial Officer and Treasurer, but will remain employed with the Company pursuant to his employment contract to assist with the transition of his duties.
공고 • Jan 05Inogen, Inc. Appoints Grgoire Ramade to Serve as Chief Commercial OfficerOn January 2, 2024, the Board of Directors (Board) of Inogen, Inc. appointed Grgoire Ramade to serve as Chief Commercial Officer (CCO) of the Company, effective January 2, 2024. Most recently, Mr. Ramade, 54, served as the company's Senior Vice President of International Sales from November 2023. Prior to joining the company, Mr. Ramade served as Senior Vice President and Chief Commercial Officer of Vapotherm, Inc. from October 2020 to October 2023 and as Vice President, International Sales and Worldwide Marketing of Vapotherm, Inc. since May 2016. Mr. Ramade worked at Becton Dickinson Medical-Pharmaceutical Systems as Vice President of Global Marketing and Business Development from January 2013 to May 2016. He also held the positions of Senior Marketing Director Home Healthcare Solution at Philips Healthcare from 2010 to 2012, Marketing Director EMEA at Philips Respironics from 2005 to 2009 and Product Manager of Consumable Masks and Accessories at Philips Respironics from 2004 to 2005. Mr. Ramade holds a bachelors degree in International Business with a minor in Economics from the American University of Paris and an MBA in International Business and Marketing from the Ecole Nationale des Ponts et Chausses School of International Management.
공고 • Nov 29Inogen, Inc. Announces Separation Agreement with Nabil ShabshabInogen, Inc. announced Nabil Shabshab Separation Agreement; Resignation as a Director. The company announced dated November 10, 2023, Mr. Shabshab’s role as an officer and employee of the Company ended effective November 10, 2023.
공고 • Nov 14+ 1 more updateInogen Announces CEO ChangesInogen, Inc. announced that its Board of Directors has appointed Kevin Smith as Inogen’s Chief Executive Officer, effective immediately, succeeding Nabil Shabshab. Mr. Smith brings more than 20 years of commercial leadership experience in the medical device industry, including respiratory care and durable medical equipment businesses, and a history of success in executing value-creating transformations across organizations. He most recently served as Chief Executive Officer at Sirtex Medical Limited, a global manufacturer of interventional treatment solutions, where he successfully implemented a profitable growth strategy, including global expansion, and oversaw the company’s business development strategy. Mr. Smith previously held senior positions at Sensium Healthcare Ltd., Teleflex, Hillrom Holdings and ZOLL Medical Corporation. Throughout his career, he has developed extensive expertise strategically navigating enterprises through market cycles, leading business turnarounds, optimizing business channels, introducing new products, and driving growth and international market expansion. Mr. Smith joins Inogen from Sirtex Medical Limited, a previously ASX-listed leading manufacturer of interventional treatment solutions, where he most recently served as Chief Executive Officer since 2019. He originally joined Sirtex in 2017 as Executive Vice President, Sales & Marketing for the Americas, and was responsible for transforming the company’s business development approach, implementing impactful commercial strategies for sustained profitable growth, and leading Sirtex’s expansion into Latin America. From October 2015 to November 2016, Mr. Smith served as Chief Commercial Officer at Sensium Healthcare Ltd., where he was responsible for revising the growth strategy, and eventually arranging a sale of the business to The Surgical Company. Earlier in his career, Mr. Smith held a variety of leadership roles in the global therapeutic and medical device industry, including a seven-year tenure at Teleflex within the cardiac business unit, where he served as Global Vice President of Sales and Marketing, and eventually International Vice President of Sales and Marketing. Key highlights of Mr. Smith’s tenure at Teleflex include leading new product launches, driving sales channel optimization initiatives and implementing strategies to improve gross margins and profitability. Mr. Smithearned an MBA in global management from the University of Phoenix and holds a Bachelor’s degree in marketing from the University of Kentucky.
Reported Earnings • Nov 10Third quarter 2023 earnings released: US$1.97 loss per share (vs US$0.41 loss in 3Q 2022)Third quarter 2023 results: US$1.97 loss per share (further deteriorated from US$0.41 loss in 3Q 2022). Revenue: US$84.0m (down 20% from 3Q 2022). Net loss: US$45.7m (loss widened 381% from 3Q 2022). Revenue is forecast to grow 4.0% p.a. on average during the next 3 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 61 percentage points per year, which is a significant difference in performance.
New Risk • Oct 29New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: €92.4m (US$97.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.4% average weekly change). Market cap is less than US$100m (€92.4m market cap, or US$97.6m).
공고 • Oct 11Inogen, Inc. to Report Q3, 2023 Results on Nov 07, 2023Inogen, Inc. announced that they will report Q3, 2023 results After-Market on Nov 07, 2023
공고 • Sep 08+ 2 more updatesInogen, Inc. Announces Executive ChangesInogen, Inc. announced that On September 1, 2023, Kristin Caltrider, Executive Vice President, Finance, Chief Financial Officer and Treasurer, notified Inogen, Inc. (the Company) of her intention to step down as an officer of the Company effective upon the date a new Executive Vice President, Chief Financial Officer and Treasurer commences employment, which will occur on September 11, 2023. Ms. Caltriders decision was not related to any disagreements with the Company or its management on any matters relating to the Companys operations, policies, or practices. Ms. Caltrider has agreed to remain in a non-executive employee role to assist with the transition of her duties through September 29, 2023. Effective as of September 11, 2023, the Companys board of directors (the Board) appointed Michael K. Sergesketter to serve as the Companys interim Executive Vice President, Chief Financial Officer and Treasurer. Mr. Michael K. Sergesketter, previously served as the Companys interim Executive Vice President, Chief Financial Officer and Treasurer from December 2021 until May 2022. Mr.Sergesketter served as the Vice President and Chief Financial Officer at Kimball Electronics, Inc., an electronics manufacturing company, from October 2014 to July 2021. Prior to the spin-off of Kimball Electronics, Mr. Sergesketter served as the Vice President and Chief Financial Officer for Kimball Electronics Group, Inc., an electronics manufacturing company, from July 1996 to October 2014. Prior to Kimball Electronics Group, Mr. Sergesketter served as Vice President of Audit and Management Services at Kimball International, Inc. from January 1991 to June 1996. Prior to that, Mr. Sergesketter held various internal audit roles at Kimball International, Inc. from June 1981 to January 1991. Mr. Sergesketter holds a B.S. in accounting from University of Southern Indiana.
Reported Earnings • Aug 08Second quarter 2023 earnings released: US$0.42 loss per share (vs US$0.15 loss in 2Q 2022)Second quarter 2023 results: US$0.42 loss per share (further deteriorated from US$0.15 loss in 2Q 2022). Revenue: US$83.6m (down 19% from 2Q 2022). Net loss: US$9.83m (loss widened 186% from 2Q 2022). Revenue is forecast to grow 1.1% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 73 percentage points per year, which is a significant difference in performance.
공고 • Aug 08Inogen, Inc. Announces the Introduction of the Rove 6(Tm) Portable Oxygen Concentrators in the United StatesInogen, Inc. announced the introduction of the Rove 6(TM) portable oxygen concentrator in the United States with best in class 8-year expected service life. The Inogen(R) Rove 6(TM) was launched in Europe in December 2022. Having completed the necessary regulatory processes, the expected service life of the Rove 6 will be extended from 5 years to 8 years for all Rove 6 devices sold worldwide. The 8 year best-in-class expected service life has also been extended to Inogen One(R) G5 portable oxygen concentrators in the US. The Inogen®? Rove 6(TM) is a 6-setting portable oxygen concentrator that also provides the longest battery life of any portable oxygen concentrator currently available on the market. This device delivers up to 1,260 mL/minute of medical grade oxygen at a weight of only 4.8 pounds. The Inogen(R") Rove 6(TM) is available with two battery options, including an extended battery that can support a battery life up to 12 hours and 45 minutes.
공고 • Aug 02Inogen, Inc. Announces Board ChangesInogen, Inc. and George Parr, Executive Vice President and Chief Commercial Officer of the Company, mutually determined that Mr. Parr would separate from the Company on or before July 31, 2023. On an interim basis, Nabil Shabshab, President and Chief Executive Officer, will manage the commercial and marketing teams to drive the Company forward and ensure business continuity during this transition period.
공고 • Jul 14+ 1 more updateInogen, Inc. to Report Q2, 2023 Results on Aug 07, 2023Inogen, Inc. announced that they will report Q2, 2023 results After-Market on Aug 07, 2023
공고 • May 07Inogen, Inc. Reiterates Earnings Guidance for the Year 2023Inogen, Inc. reiterated earnings guidance for the year 2023. The company expects total company revenue for the full year 2023 to grow in the low to mid digits. The company remains focused on its return to profitability by the fourth quarter of 2023.
Reported Earnings • May 06First quarter 2023 earnings released: US$0.88 loss per share (vs US$0.63 loss in 1Q 2022)First quarter 2023 results: US$0.88 loss per share (further deteriorated from US$0.63 loss in 1Q 2022). Revenue: US$72.2m (down 10% from 1Q 2022). Net loss: US$20.3m (loss widened 43% from 1Q 2022). Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 89 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 26Full year 2022 earnings released: US$3.67 loss per share (vs US$0.28 loss in FY 2021)Full year 2022 results: US$3.67 loss per share (further deteriorated from US$0.28 loss in FY 2021). Revenue: US$377.2m (up 5.4% from FY 2021). Net loss: US$83.8m (loss widened US$77.4m from FY 2021). Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 105 percentage points per year, which is a significant difference in performance.
공고 • Feb 11Inogen, Inc. Announces Bart Sanford to Step Down as Executive Vice President, Operations Effective on or Before March 1, 2023On February 6, 2023, Inogen, Inc. (the “Company”) and Bart Sanford, Executive Vice President, Operations of the Company, mutually determined that Mr. Sanford would separate from the Company on or before March 1, 2023. In connection with Mr. Sanford’s separation as Executive Vice President, Operations, Mr. Sanford and the Company entered into a transition agreement and release, whereby Mr. Sanford agreed to provide transition services to the Company in his current role until, at the latest, March 1, 2023.
공고 • Jan 11+ 1 more updateInogen, Inc. to Report Q4, 2022 Results on Feb 23, 2023Inogen, Inc. announced that they will report Q4, 2022 results at 4:00 PM, US Eastern Standard Time on Feb 23, 2023
Board Change • Nov 16High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Heather Rider is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Nov 03Third quarter 2022 earnings released: US$0.41 loss per share (vs US$0.54 profit in 3Q 2021)Third quarter 2022 results: US$0.41 loss per share (down from US$0.54 profit in 3Q 2021). Revenue: US$105.4m (up 13% from 3Q 2021). Net loss: US$9.51m (down 178% from profit in 3Q 2021). Revenue is forecast to grow 8.3% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 96 percentage points per year, which is a significant difference in performance.
공고 • Nov 03Inogen, Inc. Provides Revenue Guidance for the Fourth Quarter of 2022Inogen, Inc. provided revenue guidance for the fourth quarter of 2022. The company now projects revenue for the fourth quarter of 2022 to be in the range of approximately $87 million to $92 million, or approximately 14% to 20% growth year-over-year.
공고 • Oct 06Inogen, Inc. to Report Q3, 2022 Results on Nov 02, 2022Inogen, Inc. announced that they will report Q3, 2022 results Pre-Market on Nov 02, 2022
Reported Earnings • Aug 06Second quarter 2022 earnings released: US$0.15 loss per share (vs US$0.23 profit in 2Q 2021)Second quarter 2022 results: US$0.15 loss per share (down from US$0.23 profit in 2Q 2021). Revenue: US$103.4m (up 1.8% from 2Q 2021). Net loss: US$3.44m (down 168% from profit in 2Q 2021). Over the next year, revenue is forecast to grow 11%, compared to a 7.3% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 107 percentage points per year, which is a significant difference in performance.
Board Change • Aug 06High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 5 experienced directors. 1 highly experienced director. Independent Director Heather Rider is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공고 • Jul 09Inogen, Inc. to Report Q2, 2022 Results on Aug 04, 2022Inogen, Inc. announced that they will report Q2, 2022 results at 4:00 PM, US Eastern Standard Time on Aug 04, 2022
공고 • Jun 26+ 1 more updateInogen, Inc.(NasdaqGS:INGN) dropped from Russell 2000 Growth-Defensive IndexInogen, Inc.(NasdaqGS:INGN) dropped from Russell 2000 Growth-Defensive Index
공고 • May 19Inogen, Inc. Names Agnes Lee as Senior Vice President of Investor Relations and Strategic Planning, Effective May 23, 2022Inogen, Inc. announced the appointment of Agnes Lee to the position of Senior Vice President of Investor Relations and Strategic Planning, effective May 23, 2022. Agnes joins Inogen from Butterfly Network, where she served as Vice President of Investor Relations. Prior to Butterfly, she led proactive investor relations programs at Fluidigm and ResMed, Inc.
공고 • May 06+ 1 more updateInogen, Inc. Provides Earnings Guidance for the Second Quarter of 2022Inogen, Inc. provided earnings guidance for the second quarter of 2022. For the period, the company expects total revenue for the second quarter of 2022 to improve sequentially and to be in line with the same period in 2021.
Board Change • Apr 27High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Independent Director Heather Rider is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공고 • Apr 22Inogen, Inc., Annual General Meeting, Jun 08, 2022Inogen, Inc., Annual General Meeting, Jun 08, 2022, at 10:00 Pacific Standard Time. Agenda: To elect three Class II directors from the nominees described in the proxy statement; to ratify the appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2022; to approve, on an advisory and non-binding basis, executive compensation as described in this proxy statement; and to transact other business that may properly come before the Annual Meeting, or any adjournments or postponements thereof.
공고 • Apr 20Inogen, Inc. Announces Management ChangesInogen, Inc. announced that this Amendment No. 1 to Current Report on Form 8-K/A (the “Amendment”) amends the Current Report on Form 8-K of Inogen, Inc. (the “Company”) dated March 22, 2022 and filed with the Commission on March 23, 2022 (the “Original Form 8-K”), which disclosed the appointment of each of Kevin King, Mary Kay Ladone, and Glenn Boehnlein to the Board of Directors of the Company (the “Board”), effective March 22, 2022. At the time of filing of the Original Form 8-K, as disclosed in the Original Form 8-K, the Board appointed Mr. King as a member of the Audit Committee of the Board (the “Audit Committee”) and chairperson of the Compensation Committee of the Board (the “Compensation Committee”), Ms. Ladone as a member of the Audit Committee and the Compensation Committee, and Mr. Boehnlein as chairperson of the Audit Committee. At the time of filing the Original Form 8-K, no determination had been made with respect to the appointment of any such directors to the Compliance Committee of the Board (the “Compliance Committee”). This Amendment is being filed solely to report that on April 14, 2022, upon the recommendation of the Nominating and Governance Committee of the Board, the Board appointed Mr. Boehnlein to the Compliance Committee, effective immediately. Effective upon such appointment, the members of the Compliance Committee are Elizabeth Mora (Chair), Kristen Miranda, and Glenn Boehnlein.
공고 • Apr 15Inogen, Inc. to Report Q1, 2022 Results on May 05, 2022Inogen, Inc. announced that they will report Q1, 2022 results After-Market on May 05, 2022
Board Change • Apr 02High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 6 experienced directors. No highly experienced directors. Independent Director Heather Rider is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공고 • Mar 06+ 1 more updateInogen, Inc. Executive ChangesOn March 1, 2022, the Board of Directors of Inogen, Inc. appointed Kristin A. Caltrider to serve as the Company's Executive Vice President and Treasurer, effective March 21, 2022. Ms. Caltrider will succeed Michael Sergesketter, interim Executive Vice President, and Treasurer, who, on March 2, 2022, tendered his resignation as an officer of the Company effective upon the date Ms. Caltrider commences employment. Mr. Sergesketter will provide transition services pursuant to the terms of his existing offer letter with the Company through no later than June 24, 2022. Most recently, Ms. Caltrider, 54, served as the Vice President of Finance at Quidel Corporation, a manufacturer of medical diagnostic products, since June 2014.
Reported Earnings • Feb 26Full year 2021 earnings: Revenues and EPS in line with analyst expectationsFull year 2021 results: US$0.28 loss per share (down from US$0.27 loss in FY 2020). Revenue: US$358.0m (up 16% from FY 2020). Net loss: US$6.33m (loss widened 8.6% from FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 4.0%, compared to a 11% growth forecast for the industry in Germany. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 70 percentage points per year, which is a significant difference in performance.
공고 • Jan 30Loren McFarland Not to Stand for Re-Election as Director of Inogen, IncOn January 6, 2022, Loren McFarland informed Inogen, Inc. that he will not stand for re-election at the Company’s 2022 annual meeting of stockholders.
공고 • Jan 12Inogen, Inc. Provides Preliminary Unaudited Revenue Guidance for the Three-Month and Twelve-Month Periods Ended December 31, 2021Inogen, Inc. provided preliminary unaudited revenue guidance for the three-month and twelve-month periods ended December 31, 2021. For the three months, the company expects revenue to be in the range of $75.9 to $76.9 million, up 2.6% to 3.9% from the same period in 2020.For the year, the company expects revenue to be in the range of $357.5 to $358.5 million, up 15.9% to 16.2% from 2020.
Reported Earnings • Nov 07Third quarter 2021 earnings released: EPS US$0.54 (vs US$0.077 loss in 3Q 2020)The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: US$93.1m (up 25% from 3Q 2020). Net income: US$12.2m (up US$13.9m from 3Q 2020). Profit margin: 13% (up from net loss in 3Q 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 05Second quarter 2021 earnings released: EPS US$0.23 (vs US$0.12 in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: US$101.6m (up 42% from 2Q 2020). Net income: US$5.10m (up 98% from 2Q 2020). Profit margin: 5.0% (up from 3.6% in 2Q 2020).
공고 • Jun 28+ 4 more updatesInogen, Inc.(NasdaqGS:INGN) dropped from Russell 3000E Value IndexInogen, Inc.(NasdaqGS:INGN) dropped from Russell 3000E Value Index